Incyte Corporation (INCY)

Nasdaq · Healthcare · Biotechnology
$114.62-1.07%As of 2026-11-22 · USD
Last session low $114.28Last session high $117.51
52-week low $89.2552-week high $132.60
Market cap
$23.36B
Sector
Healthcare
P/E (TTM)
58.5x

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)43.6In the neutral range (30 to 70)
MACD (12, 26, 9)0.04Below its signal line (0.51); histogram -0.47
Bollinger %B (20, 2)7%Inside the bands (113.91 to 123.88)
SMA 20118.90Price is 3.6% below
SMA 50118.51Price is 3.3% below
SMA 200109.32Price is 4.9% above
ATR (20)3.16% of priceAverage true range per day
52-week position59%In the middle of the 89.25 to 132.60 range

About Incyte Corporation

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.

Insider filings, 90 daysNo purchases and 3 sales (about $3.2M).
Latest fiscal yearEnded 2025-12-31: revenue of $5.14B and an operating margin of 26.1%.

More in Biotechnology